Conmed Q2 2024 Adj. EPS $0.98 Beats $0.91 Estimate, Sales $332.097M Miss $332.325M Estimate
Portfolio Pulse from Benzinga Newsdesk
Conmed (NYSE:CNMD) reported Q2 2024 adjusted EPS of $0.98, beating the estimate of $0.91. However, sales of $332.097 million missed the estimate of $332.325 million. Sales increased by 4.55% compared to the same period last year.

July 31, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Conmed's Q2 2024 adjusted EPS of $0.98 beat estimates by 7.69%, but sales of $332.097 million slightly missed expectations. Sales increased by 4.55% YoY.
The beat on EPS is a positive indicator and likely to boost investor confidence, despite the slight miss on sales. The YoY sales increase further supports a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100